黑色素瘤的新疗法:当前趋势,不断发展的范式和未来的前景
Saba Shafi1, Bindu Challa1, Anil V Parwani1
1Dr. Shafi, Bindu Challa, and Dr. Parwani are from the Department of Pathology & Laboratory Medicine, The Ohio State University Wexner Medical Center, Columbus. Dr. Aung is from the Department of Pathology & Laboratory Medicine, Yale School of Medicine, Yale University, New Haven, Connecticut.
Cutis
|December 13, 2023
概括
新的黑色素瘤治疗方法,包括免疫检查点抑制剂 (ICI) 和纳米技术,对抗现有疗法耐药的患者显示出有前途. 研究正在探索新的点,如淋巴细胞激活基因3 (LAG-3) 和组合策略,以改善结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 纳米技术纳米技术
背景情况:
- 黑色素瘤的发病率和死亡率在全球范围内不断上升,历史上治疗选择有限.
- 最近的进展包括免疫检查点抑制剂 (ICI) 和向疗法,彻底改变了转移性黑色素瘤护理.
- 然而,许多患者缺乏ICI的长期益处,需要替代策略和新的点,如淋巴细胞激活基因3 (LAG-3).
研究的目的:
- 在早期临床试验中审查新兴治疗剂和黑色素瘤的新组合.
- 探索基于纳米技术的纳米系统在改善黑色素瘤治疗方面的潜力.
- 突出管理治疗耐药性的挑战,并确定针对性治疗的预测生物标志物.
主要方法:
- 关于新型黑色素瘤治疗方法的当前文献的综述.
- 对新药和组合的早期临床试验数据的分析.
- 探索纳米技术在药物输送和光热治疗黑色素瘤中的应用.
主要成果:
- 新兴疗法和新组合正在早期临床试验中进行研究.
- 纳米技术为先进的药物输送和增强治疗疗效提供了潜力.
- 仍然存在重大挑战,包括克服治疗耐药性和开发预测生物标志物.
结论:
- 针对淋巴细胞激活基因3 (LAG-3) 和利用纳米技术的新型治疗策略对于推进黑色素瘤治疗至关重要.
- 基于预测生物标志物的组合疗法和个性化方法对于改善患者的治疗结果至关重要.
- 解决治疗耐药性和耐药性机制是先进黑色素瘤护理未来研究的重点.
相关概念视频
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Skin Cancer
4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Vaccines
376
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
376
Current Trends in Nursing II
1.2K
Trends in nursing are multifactorial and associated with changes in society, within the nursing profession, and in other professions. Notably, telehealth and remote nursing contribute to successful healthcare delivery for numerous patients and help reduce stress for nurses due to nursing shortages. Nurses can reach patients, monitor their conditions, and interact with them using computers, audio, visual accessories, and telephones—for example, remote patient monitoring systems. Likewise,...
1.2K


